PERRIGO COMPANY PLC
PRGOPerrigo Company PLC is a global healthcare company specializing in the development, manufacture, and distribution of over-the-counter (OTC) healthcare products, including self-care, infant nutrition, and pharmacy generics. Headquartered in Ireland, Perrigo is known for providing affordable healthcare products across various markets, with a strong presence in North America and Europe. The company focuses on consumer wellness and pharmaceutical products designed to improve health and wellness for consumers worldwide.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| $0.01 | 2013-12-19 | ||
| June 16, 2026 | $0.29 | 2026-05-29 | 2026-05-29 |
| March 24, 2026 | $0.29 | 2026-03-02 | 2026-03-02 |
| December 16, 2025 | $0.29 | 2025-11-28 | 2025-11-28 |
| September 16, 2025 | $0.29 | 2025-08-29 | 2025-08-29 |
Dividends Summary
- Total Returned Value: Investors who held PRGO shares during this period received a total of $12.87 per share in dividend income.
- Latest Payout: The most recent dividend of $0.01/share was paid 32 days ago, on June 16, 2026.
- Dividend Growth: Since 2004, the dividend payout has decreased by 71.4%, from $0.04 to $0.01.
Company News
Perrigo Company plc announced that its Board of Directors has approved a quarterly dividend of $0.29 per share ($1.16 annualized). The dividend is payable on June 16, 2026, to shareholders of record on May 29, 2026.
The article examines three high-yielding healthcare stocks: Perrigo (9.6% yield) faces growth slowdown and profitability pressure despite a 23-year dividend streak; Healthpeak Properties (7.1% yield) offers potential upside through its Janus Living spinoff; Medical Properties Trust (6.8% yield) has stabilized after significant dividend cuts due t...
The article highlights five small-cap stocks offering high dividend yields (6.6%-11%) that remain undervalued despite strong 2026 performance. The author recommends regional banks and energy companies as income-generating opportunities, though warns of risks including economic sensitivity and potential dividend sustainability concerns.
Good Start® | Dr. Brown's™ infant formula has been named 'Baby Food Product of the Year' at the 2025 Baby Innovation Awards. The partnership combines Good Start's 50+ year heritage with Dr. Brown's pediatrician-recommended bottles to offer tolerance-focused infant formulas including Soothe Pro®, Gentle Pro®, and Soy-ease Pro® variants desig...
The global scar treatment market is projected to grow from USD 26.60 billion in 2025 to USD 56.30 billion by 2033, with a CAGR of 9.91%. Growth is driven by increasing awareness of advanced cosmetic and reconstructive procedures, rising prevalence of acne, surgical, and traumatic scars, and technological advancements in minimally invasive treatme...
